Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock

DALLAS, TEXAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that its former wholly-owned subsidiary, MangoRx IP Holdings, LLC ("MangoRx IP"), has entered into subscription agreements with two strategic investors for an aggregate investment of $2.5 million directly into MangoRx IP, and has received the first tranche of $1.75 million due thereunder. Importantly, the investments are being made at the subsidiary level and do not involve the issuance of any shares of Mangoceuticals common stock, warrants or other securities of the publicly-traded parent company. Accordingly, the transactions do not increase the number of outstanding shares of Mangoceuticals or otherwise impact the Company’s public capitalization structure.

Under the terms of the agreements, the investors have committed to purchase an aggregate 25% membership interest in MangoRx IP for $2.5 million, payable in two tranches. The initial tranche consists of the equivalent of a 17.5% membership interest on a post-acquisition basis for $1.75 million, and the second tranche consists of the remaining 7.5% membership interest for $750,000, payable within 60 days following the initial closing, or by November 28, 2026, subject to the terms and conditions of the applicable subscription agreement.